DBC1 does not function as a negative regulator of SIRT1 in liver cancer

Hyun Jin Bae, Young Gyoon Chang, Ji Heon Noh, Jeong Kyu Kim, Jung Woo Eun, Kwang Hwa Jung, Min Gyu Kim, Qingyu Shen, Young Min Ahn, So Hee Kwon, Won Sang Park, Jung Young Lee, Suk Woo Nam

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


The putative tumor suppressor, DBC1 (deleted in breast cancer-1), was recently found to negatively regulate SIRT1 in vitro and in vivo, but the mechanism whereby DBC1 regulates SIRT1 in liver cancer remains to be elucidated. In this study, it was found that although the expression of DBC1 and SIRT1 was not aberrantly regulated in a large cohort of human hepatocellular carcinoma (HCC) patients, these proteins were highly overexpressed in a subset of HCC tissues compared with surrounding non-cancer tissues. In liver cancer, DBC1 and SIRT1 were found to be positively correlated. Inactivation of DBC1 or SIRT1 reduced SNU-182 (a liver cancer cell line) proliferation as determined by MTT viability assays. Notably, although DBC1 functions as a negative regulator of SIRT1 in A549 lung cancer cells since it suppresses the deacetylase activity of the p53 protein, it did not affect the p53 deacetylase activity of SIRT1 in SNU-182 cells. Taken together, we conclude that DBC1 is associated with SIRT1 in HCC, but that it does not inhibit SIRT1.

Original languageEnglish
Pages (from-to)873-877
Number of pages5
JournalOncology Letters
Issue number5
Publication statusPublished - 2012 Nov

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'DBC1 does not function as a negative regulator of SIRT1 in liver cancer'. Together they form a unique fingerprint.

Cite this